BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33772456)

  • 21. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
    Han Y; Shi JP; Ma AL; Xu Y; Ding XD; Fan JG
    Clin Drug Investig; 2014 Jan; 34(1):1-7. PubMed ID: 24081374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial.
    Alam S; Kabir J; Mustafa G; Gupta U; Hasan SK; Alam AK
    Saudi J Gastroenterol; 2016; 22(1):69-76. PubMed ID: 26831610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease.
    Aller R; Laserna C; Rojo MÁ; Mora N; García Sánchez C; Pina M; Sigüenza R; Durà M; Primo D; Izaola O; de Luis D
    Rev Esp Enferm Dig; 2018 Oct; 110(10):634-640. PubMed ID: 30032630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
    Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.
    Klaebel JH; Skjødt M; Skat-Rørdam J; Rakipovski G; Ipsen DH; Schou-Pedersen AMV; Lykkesfeldt J; Tveden-Nyborg P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
    Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
    Della Corte C; Carpino G; De Vito R; De Stefanis C; Alisi A; Cianfarani S; Overi D; Mosca A; Stronati L; Cucchiara S; Raponi M; Gaudio E; Byrne CD; Nobili V
    PLoS One; 2016; 11(12):e0168216. PubMed ID: 27977757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.
    Kugelmas M; Hill DB; Vivian B; Marsano L; McClain CJ
    Hepatology; 2003 Aug; 38(2):413-9. PubMed ID: 12883485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.